Roeker, Lindsey E.

Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors

Wang, E., Mi, X., Thompson, M. C., Montoya, S., Notti, R. Q., Afaghani, J., Durham, B. H., Penson, A., Witkowski, M. T., Lu, S. X., et al. (2022) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 272

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M. C., Chirino, A., Jahn, J., Sondhi, A. K., Gajewski, S., Tan, Y. S. (., et al. (2024) · Science

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 175

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Mato, A. R., Wierda, W. G., Ai, W. Z., Flinn, I. W., Tees, M., Patel, M. R., Patel, K., O'Brien, S., Bond, D. A., Roeker, L. E., et al. (2022) · Blood

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 74

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Ghosh, N., Lamanna, N., Eyre, T. A., Coombs, C. C., Manzoor, B. S., Brown, J. R., Tuncer, H. H., Ujjani, C. S., Leslie, L. A., Roeker, L. E., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 6